Teen cannabis use doubles the risk of serious mental disorders

Introduction: a massive study that upends assumptions

More than 463,000 teens tracked

A study published in JAMA Health Forum, involving 463,396 adolescents ages 13 to 17 at baseline and followed until age 26, finds that cannabis use among young people roughly doubles the risk of developing psychotic or bipolar disorders, according to ScienceDaily.

Led by researchers from Kaiser Permanente, the University of California, San Francisco, and the University of Southern California, this research draws on electronic health record data collected between 2016 and 2023 during routine pediatric visits.

A public health issue that deserves plain language, not drama

This study, funded by the National Institute on Drug Abuse, deserves particular attention not to fuel moral panic about cannabis, but because it offers rare longitudinal data on a public health question that directly affects millions of North American families.

My goal in this editorial is to make these findings accessible without distorting them, neither in an alarmist direction nor a dismissive one, an editorial line I try to hold on every medical topic covered in this column.

What the numbers precisely reveal

A doubled risk for two major disorders

According to the published data, adolescents who reported cannabis use in the previous year had roughly double the risk of developing a psychotic disorder or a bipolar disorder, even after statistically adjusting for mental health history and use of other substances.

Researchers also found an increased risk of depression and anxiety among young users, though the strength of that association was less pronounced than for the psychotic and bipolar disorders specifically studied.

An average lag of less than two years before diagnosis

A particularly striking finding noted by the researchers: cannabis use preceded the psychiatric diagnosis by an average of 1.7 to 2.3 years, a relatively short interval that strengthens the hypothesis of a causal link rather than a mere statistical coincidence.

This tight gap between exposure and diagnosis is one of the study's strongest elements, since it limits the likelihood that other unmeasured external factors fully explain the association observed by the researchers.

A potency of cannabis very different from the past

THC levels sharply on the rise

The study highlights a context often forgotten in public debate: the average THC content of cannabis flower sold in California now exceeds 20 percent, while some concentrates can reach more than 95 percent THC, levels with no comparison to the cannabis consumed a few decades ago.

This shift in the potency of available products complicates any direct comparison with older cannabis studies, making updated research like this one all the more relevant for assessing the real risks tied to products currently in circulation.

Teen use that is already widespread

Cannabis remains the most commonly used illicit drug among American teens, with prevalence rising from about 8 percent in eighth grade to 26 percent in twelfth grade, according to data cited in the study, and more than 10 percent of young people ages 12 to 17 reporting use in the previous year.

This wide reach, combined with the increased potency of today's products, creates a new health landscape that fully justifies the attention this study is receiving from North American public health professionals.

Social inequalities that worsen the picture

More frequent use among disadvantaged populations

The study notes that cannabis use among adolescents was more common among those enrolled in Medicaid and among those living in neighborhoods marked by greater socioeconomic disadvantage, a finding that adds a social-equity dimension to this public health issue.

This disparity suggests that the potential health consequences of this use could disproportionately affect populations already facing limited access to specialized mental health care.

An issue that goes beyond individual choice alone

Reducing this question to a simple individual choice by the adolescents involved would mean ignoring the structural, economic and social factors that heavily influence early exposure to cannabis among certain more vulnerable populations.

This social dimension deserves to be built into any public prevention policy, rather than limiting efforts to generic awareness campaigns that ignore unequal access to mental health support resources.

What this study does not yet prove

A strong association, but not absolute causal proof

Despite the methodological soundness of this longitudinal study, the researchers themselves remain cautious: a robust statistical association, even one adjusted for several confounding factors, does not constitute definitive, irrefutable proof of a direct causal link between cannabis and psychiatric disorders.

This methodological nuance, essential to scientific rigor, should not, however, serve as an excuse to ignore a statistical signal this consistent and repeated across recent scientific literature on this specific subject.

Questions that remain open for future research

Researchers have not yet fully determined whether certain subgroups of adolescents, due to specific genetic or environmental factors, show a particularly heightened vulnerability to the potential effects of cannabis on developing mental health.

This legitimate area of uncertainty calls for more targeted research, rather than hasty conclusions in either direction on this complex issue that affects millions of families.

A measured hope: better prevention rather than panic

The importance of early screening in pediatrics

This study strengthens the case for systematic screening of cannabis use during routine pediatric visits, a practice that could enable early intervention before more severe psychiatric symptoms appear among at-risk adolescents.

This kind of universal screening, already used within the methodological framework of this study, illustrates a concrete, immediately applicable path for North American health systems eager to act on these findings without waiting years for further research.

Information without excessive moral judgment

The hope I take from this study is not for another wave of punitive prohibition, but for more precise, accessible information for families and adolescents themselves, so they can make informed decisions about products whose potency has changed considerably.

This informative approach, rather than a moralizing one, seems to me the most promising way to translate these scientific findings into concrete benefits for the mental health of North America's younger generations.

How clinicians are receiving these findings

A clinical confirmation of concerns already observed

Several child psychiatrists quoted in media coverage of the study say these findings confirm clinical observations they had already informally noted for several years in their practices, though until now without such extensive data to statistically support these professional impressions.

This convergence between daily clinical experience and large-scale epidemiological data strengthens the overall credibility of this study's conclusions within the North American medical community.

Practical recommendations for families

Health professionals now more consistently recommend openly discussing cannabis with adolescents, emphasizing the differences in potency between today's products and those used by previous generations of parents.

This conversational approach, rather than a purely punitive one, aligns directly with the spirit of the study, which aims to inform rather than stigmatize occasional or regular young users.

The broader debate over legalization and its effects

Legalization that complicates targeted prevention

The gradual legalization of cannabis in several American states and Canadian provinces has fueled the development of ever more potent and diverse products, a commercial evolution that paradoxically complicates targeted prevention efforts aimed at adolescents.

This tension between growing social acceptance of cannabis among adults and the specific risks documented among adolescents illustrates the complexity of the public policies needed to reconcile individual freedom with protecting minors' health.

Stricter regulation for high-potency products

Some public health experts now argue for stricter regulatory oversight of very high-THC products, particularly concentrates exceeding 95 percent, arguing that these products carry risks specifically different from those of the traditional cannabis studied in older research.

This proposal for regulation differentiated by product potency illustrates a concrete path lawmakers could explore in light of this recent study's findings.

Conclusion: a study meant to inform, not frighten

A serious scientific signal to be taken seriously

This study of more than 463,000 adolescents stands as one of the strongest signals to date on the link between cannabis use in adolescence and increased risk of psychiatric disorders, a finding that deserves wide distribution among families and health professionals.

Without giving in to moral panic or convenient denial, this research calls for a more honest conversation about the real potency of today's products and the importance of early screening in pediatric settings.

Toward prevention grounded in facts rather than fear

The best response to these scientific findings is probably not a new wave of moralizing prohibition, but a renewed education effort grounded in solid data, tailored to the realities of today's cannabis rather than those of a generation ago.

This balanced path, between scientific vigilance and respect for the autonomy of families, is the one I will keep defending in covering public health issues affecting our youth.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and my limits

I am a columnist for MadMax, not a mental health researcher or a doctor. This analysis rests exclusively on the study published in JAMA Health Forum and its coverage by recognized science outlets.

I do not claim to definitively settle a complex scientific debate; I am explaining published findings in plain language while explicitly flagging their methodological limits, as acknowledged by the researchers themselves.

My verification method

I directly consulted the summary of the study published on PMC, as well as its coverage by ScienceDaily and MedicalXpress, avoiding any extrapolation not supported by the data actually published by the researchers.

I did not invent any statistic or any quote; every figure cited in this text comes directly from the sources listed below.

Sources

Primary sources

ScienceDaily, Massive study links teen marijuana use to double the risk of serious mental illness — July 3, 2026

PMC, Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders

JAMA Health Forum, full study (DOI)

Secondary sources

MedicalXpress, Cannabis caution: psychosis risk in young people — June 2026

World News, Massive study links teen marijuana use to double the risk — June 28, 2026

ScienceDaily, Health & Medicine section